These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31613955)

  • 1. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.
    Combier A; Nocturne G; Henry J; Belkhir R; Pavy S; Le Tiec C; Descamps E; Seror R; Mariette X
    Rheumatology (Oxford); 2020 Jun; 59(6):1347-1354. PubMed ID: 31613955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
    Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
    Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis.
    Md Yusof MY; Iqbal K; Darby M; Lettieri G; Vital EM; Beirne P; Dass S; Emery P; Kelly C
    Rheumatology (Oxford); 2020 Oct; 59(10):2838-2846. PubMed ID: 32065634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
    Mariette X; Gottenberg JE; Ravaud P; Combe B
    Rheumatology (Oxford); 2011 Jan; 50(1):222-9. PubMed ID: 21148156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study.
    Lazarou I; Finckh A; Fischer L; Ribi C; Gascon D; Seebach JD; Guerne PA
    Joint Bone Spine; 2016 Mar; 83(2):191-7. PubMed ID: 26677998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
    Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of rituximab in resistant palindromic rheumatism: first report in literature.
    Raghavan P; Sreenath S; Cherian S; Shenoy PD
    Clin Rheumatol; 2019 Sep; 38(9):2399-2402. PubMed ID: 31076945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
    Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
    Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study.
    Dumusc A; Alromaih F; Perreau M; Hügle T; Zufferey P; Dan D
    Arthritis Res Ther; 2023 Jun; 25(1):91. PubMed ID: 37264414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
    Shim SC; Božić-Majstorović L; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Cons Molina FF; Medina-Rodriguez FG; Miranda P; Shesternya P; Chavez-Corrales J; Wiland P; Jeka S; Garmish O; Hrycaj P; Fomina N; Park W; Suh CH; Lee SJ; Lee SY; Bae YJ; Yoo DH
    Rheumatology (Oxford); 2019 Dec; 58(12):2193-2202. PubMed ID: 31184752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion.
    Pérez-Sánchez C; Cecchi I; Barbarroja N; Patiño-Trives AM; Luque-Tévar M; Pérez-Sánchez L; Ibáñez-Costa A; Arias de la Rosa I; Ortega R; Escudero A; Castro MC; Radin M; Roccatello D; Sciascia S; Aguirre MÁ; Collantes E; López-Pedrera C;
    J Cell Mol Med; 2019 Sep; 23(9):6308-6318. PubMed ID: 31347786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
    Reddy V; Klein C; Isenberg DA; Glennie MJ; Cambridge G; Cragg MS; Leandro MJ
    Rheumatology (Oxford); 2017 Jul; 56(7):1227-1237. PubMed ID: 28407142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience.
    Braun-Moscovici Y; Butbul-Aviel Y; Guralnik L; Toledano K; Markovits D; Rozin A; Nahir MA; Balbir-Gurman A
    Rheumatol Int; 2013 Jun; 33(6):1495-504. PubMed ID: 23239037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.
    Sebastiani M; Anelli MG; Atzeni F; Bazzani C; Farina I; Fedele AL; Favalli EG; Fineschi I; Cino N; Dal Forno I; Gasparini S; Cassarà E; Giardina R; Bruschi E; Addimanda O; Cassone G; Lopriore S; Sarzi-Puttini P; Filippini M; Pignatti F; Gremese E; Biggioggero M; Manganelli S; Amato G; Caimmi C; Salaffi F; Iannone F; Ferri C; Sandri G; Lapadula G; Gorla R; Govoni M; Ferraccioli G; Marchesoni A; Galeazzi M; Foti R; Carletto A; Cantini F; Triolo G; Epis OM; Salvarani C;
    Joint Bone Spine; 2014 Dec; 81(6):508-12. PubMed ID: 25082646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
    Park W; Suh CH; Shim SC; Molina FFC; Jeka S; Medina-Rodriguez FG; Hrycaj P; Wiland P; Lee EY; Shesternya P; Kovalenko V; Myasoutova L; Stanislav M; Radominski S; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Yoo DH
    BioDrugs; 2017 Aug; 31(4):369-377. PubMed ID: 28600696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
    Galarza C; Valencia D; Tobón GJ; Zurita L; Mantilla RD; Pineda-Tamayo R; Rojas-Villarraga A; Rueda JC; Anaya JM
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):124-8. PubMed ID: 18270866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
    Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
    BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
    Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
    Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis.
    Giraud C; Tatar Z; Soubrier M
    Clin Rheumatol; 2016 Oct; 35(10):2615-8. PubMed ID: 27541023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.